Skip to content
Screener

G&A at other companies

Candel Therapeutics, Inc. logo
Candel Therapeutics, Inc.CADL
$6.44M+56.6%
Regenxbio logo
RegenxbioRGNX
$21.62M+8.7%
Immunome logo
ImmunomeIMNM
$12.95M+21.1%
CG Oncology logo
CG OncologyCGON
$28.98M+66.4%
OnKure Therapeutics, Inc. logo
OnKure Therapeutics, Inc.OKUR
$3.91M-2.0%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$1.01B+160%
Enterprise value$967.91M+162%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The source filing: Replimune Group’s 10-Q, filed February 3, 2026.

Filed
Feb 3, 2026, 8:12 AM EST
Fiscal quarter
Q3 FY2026
Calendar quarter
Q4 2025
Accession
0001628280-26-004805
Line itemThree Months Ended December 31, 2025Three Months Ended December 31, 2024Nine Months Ended December 31, 2025Nine Months Ended December 31, 2024
Operating expenses:
Research and development$53,140$48,004$168,860$135,472
Selling, general and administrative18,72818,01577,72146,827
Total operating expenses71,86866,019246,581182,299
Loss from operations(71,868)(66,019)(246,581)(182,299)
Other income (expense):
Research and development incentives3413761,1381,222
Investment income2,8465,13711,25615,243

Item 1. Condensed Consolidated Financial Statements (Unaudited)

FAQ

What is Replimune Group's G&A?
Replimune Group (REPL) reported G&A of $18.73M in Q4 2025.
How has Replimune Group's G&A changed year-over-year?
Replimune Group's G&A increased by 4.0% year-over-year, from $18.02M to $18.73M.
What is the long-term trend for Replimune Group's G&A?
Over 3 years (2022 to 2025), Replimune Group's G&A has grown at a 23.6% compound annual growth rate (CAGR), from $38.77M to $73.23M.
What does G&A mean?
Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.

Ask your AI about Replimune Group's g&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude